Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just copied and pasted. popsitive show with no brackets and negatives show with brackets according to normal accounting standars. Thanks
You should put (-) between numbers! very cofusing numerical format!
the moderator
September 30, September 30, September 30, September 30, September 30,
2009 2008 2009 2008 2009
Revenue $ — $ — $ — $ — $ —
Operating costs and expenses:
Research and development 1,306,309 3,155,013 4,949,118 9,593,202 39,800,081
General and administration 1,697,476 1,869,366 5,491,380 6,641,138 27,339,113
Merger transaction costs — — — — 3,824,090
Total operating costs and expenses 3,003,785 5,024,379 10,440,498 16,234,340 70,963,284
Operating loss (3,003,785 ) (5,024,379 ) (10,440,498 ) (16,234,340 ) (70,963,284 )
Other income (expense):
Interest income — 32,002 — 185,195 914,628
Interest expense (5,033,598 ) (3,891 ) (6,299,768 ) (4,106 ) (7,304,861 )
Other (expense) income (663 ) 28,996 8,893 5,732 (4,097 )
Total other income (expense) (5,034,261 ) 57,107 (6,290,875 ) 186,821 (6,394,330 )
Net Loss $ (8,038,046 ) $ (4,967,272 ) $ (16,731,373 ) $ (16,047,519 ) $ (77,357,614 )
Loss per share of common stock—basic and diluted $ (0.40 ) $ (0.25 ) $ (0.84 ) $ (0.82 )
Weighted-average shares outstanding—basic and diluted 20,014,457 19,620,757 19,875,482 19,594,397
See notes to the unaudited condensed financial statements.
2
10q info
September 30, December 31,
2009 2008
ASSETS
Current assets:
Cash and cash equivalents $ 4,591,488 $ 4,064,545
Prepaid expenses and other current assets 276,972 604,080
Total current assets 4,868,460 4,668,625
Property and equipment-net 203,323 291,804
Other non-current assets 40,374 40,374
Total $ 5,112,157 $ 5,000,803
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 330,386 $ 753,824
Accrued expenses and other liabilities 2,630,402 2,652,458
Interest payable — affiliate 410,959 —
Notes payable — affiliate — net of discount of $1,059,914 8,940,086 —
Total current liabilities 12,311,833 3,406,282
Deferred rent 36,599 30,637
Total liabilities 12,348,432 3,436,919
Commitments and contingencies
Stockholders’ equity (deficit):
Common stock, $0.001 par value-200,000,000 shares authorized at September 30, 2009 and December 31, 2008; 20,646,374 and 20,592,718 shares issued and outstanding at September 30, 2009 and December 31, 2008, respectively 20,646 20,593
Preferred stock Series A, $0.001 par value-5,000,000 shares authorized at September 30, 2009 and December 31, 2008; 0 shares issued and outstanding at September 30, 2009 and December 31, 2008 — —
Convertible preferred stock Series C, $0.001 par value-17,000 shares authorized at September 30, 2009 and December 31, 2008; 2,000 shares issued and outstanding at September 30, 2009 and December 31, 2008; liquidation preference of $2,000,000 2 2
Additional paid-in capital 70,100,691 62,169,530
Deficit accumulated in the development stage (77,357,614 ) (60,626,241 )
Total stockholders’ equity (deficit) (7,236,275 ) 1,563,884
Total $ 5,112,157 $ 5,000,803
See notes to the unaudited condensed financial statements.
1
more to go also.
VIAP - VIA PHARMACEUTICALS INC (NASDAQd)
Date Open High Low Last Change Volume % Change
11/09/09 0.37 0.47 0.37 0.45 +0.07 410968 +18.42%
Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold
Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 259693
Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Sell
Medium Term Indicators Average: 25% - Buy
50-Day Average Volume - 209169
Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Sell
Long Term Indicators Average: - Hold
100-Day Average Volume - 165821
Overall Average: 48% - Buy
Price Support Pivot Point Resistance
0.45 0.33 0.43 0.53
VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
VIA-3196 THR Beta Agonist Featured in Abstract Oral Session
SAN FRANCISCO, Nov. 4 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (NASDAQ:VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "VIA-3196, a Liver-directed Thyroid Beta Agonist for Treating Cardiometabolic Disease" in the Abstract Oral Session on Novel Biological Mechanisms of Atherosclerosis November 17, 2009 at the American Heart Association Scientific Sessions 2009 in Orlando, Florida.
The presentation details are as follows:
Date / Time: Tuesday November 17, 2009 9:15 am ET Location: Orange County Convention Center, Orlando, Florida Room W304cd Session: Abstract Oral Session - Novel Biological Mechanisms of Atherosclerosis Title: VIA-3196, a Liver-directed Thyroid Beta Agonist for Treating Cardiometabolic Disease
About THR beta agonist
VIA-3196 is an orally administered, small-molecule beta-selective thyroid hormone receptor agonist designed to specifically target receptors in the liver involved in metabolism and cholesterol regulation, and avoid side effects associated with thyroid hormone receptor activation outside the liver. Roche has completed preclinical studies of the THR beta agonist. These studies demonstrated a rapid reduction of non-HDL cholesterol and the drug was shown to be synergistic with statins in animal studies. VIA will investigate the possibility of using the THR beta agonist in combination with statins for the treatment of hypercholesterolemia. In addition, in animal studies, insulin sensitization and glucose lowering were observed making this compound a possible treatment of patients with type 2 diabetes in combination with other diabetes medications.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com/.
VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
http://ih.advfn.com/p.php?pid=nmona&cb=1256834003&article=40115218&symbol=N^VIAP
I think it will... Any news will make this stock go up, imo.
JMO.
GLTA!
A big drop today, hopefully it will recover.
It has been green the past few days, so some selling is not all that bad. IMO, people are mainly waiting on news here...
JMO.
GLTA!
From an SEC Form 10-K. Filed March 27, 2009:
In addition to the CEA and ACS Phase II clinical trials, the Company is currently conducting a third Phase II clinical trial involving VIA-2291 that utilizes FDG-PET to measure the impact of VIA-2291 on reducing vascular inflammation in treated patients. The Company plans to enroll approximately 50 patients following an acute coronary syndrome event, such as heart attack or stroke, into the 24 week, randomized, double blind, placebo-controlled study. Endpoints in the study include reduction in plaque inflammation as measured with FDG-PET, as well as assessment of standard biomarker measurements of inflammation. The FDG-PET clinical trial is expected to be completed and data reported in the second half of 2009.
Link: http://www.sec.gov/Archives/edgar/data/1003929/000095013409006232/f51890e10vk.htm
Top of page 8.
BTW, doesn't VIA have to find a way to pay Bay City Capital by 10/31? Once they release some news on how they're going to accomplish that, it could go over $1 imo. Especially if it's partnership news... VIAP reminds me of OPXA when they were trading .40-.50, and partnership news shot OPXA over $2.
JMO.
GLTA!
No problem! Thanks! :)
Camaro; thnx. excellent job!
Added some PRs about the merger with Corautus, and highlighted the 1:15 Reverse Stock split under "Stock Info".
If there's anything else, just let me know!
GLTA!
Camaron ; Historically two events are important: Failure of VIAP and its acquisition thereafter; and the reverse split.. Long term investors should know about these two things before getting in.
Thnx
Thanks! iBox updated! If there's anything missing that needs adding let me know...
GLTA.
Looking good, VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
Looking good... BTW, if you need some help on the iBOX, add me as an assistant and I can work on it...
GLTA!
Move up for change on yesterday's news for favorable listing hearing by NAZDOG and 800 k volume! Shares bought in 030s being sold @ o40s..
VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
SAN FRANCISCO, Oct. 13 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (NASDAQ:VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market ("NASDAQ") notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period"). During the Exception Period, the Company must provide prompt notification of any significant events to NASDAQ.
The Panel granted the Company's request after a hearing held on August 27, 2009 in which the Company presented its plan of compliance (the "Plan") with respect to its failure to satisfy NASDAQ's minimum $2.5 million stockholders' equity, board independence, and $1.00 minimum bid price requirements for continued listing. Based on the Company's Plan and its continued execution of the Plan, the Panel found that it was appropriate to allow the Company to remain listed on NASDAQ while the Company works to regain compliance with the Listing Rules.
There can be no assurance that the Company will be able to achieve or sustain the requirements under the Listing Rules to insure that it will maintain its NASDAQ listing.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com/.
Forward Looking Statements
I'll continue to watch it. I do think they have the right approach to the science... and it obviously will be useful to have them succeed in refining their understanding and applying the science to solve the problem...
If and when they solve the problem, the solution will be hugely valuable...
What we see now appears it can be only one of two things...
It is either large and significant uncertainty on the part of those who are closest to the issues, with Bay seeming to be waffling on the edge of indecision about what to do with the project, so posturing in a way that has them sitting on VIAP pretty hard. Basically, in that scenario, Bay has recalled it for some serious reworking of the effort from the concept level... and they've repo'd it to make keeping it alive make sense to them.
Otherwise, there is some more significant success occurring in the science side than we are being let in on, and Bay is doing what they are in posturing it as they are only in order to capture far more of the value that exists then would appear justified if the level of uncertainty being postured weren't looking to us like it does.
My opinion is that I don't know which of those is closer to the ground truth... and it doesn't matter from an investment perspective to the degree that the impact is the same.
Given what I have seen here more recently, I'm leaning more toward the first of the two options... I think it likely Bay's analysis is more clearly focused on "$ required vs. the timelines" with greater clarity than we CAN have. Given the track record, I'm thinking they are probably less wrong on the programmatic elements as VCs then they are on top of the value and utility of the work done on the science side.
I do think the science effort has been under-managed... perhaps a bit more going through the motions than applying intellect to the problems as they go...
What I don't get, yet, is why, IF it is back to the level of being a basic science project that will need to start over from scratch on the FDA phase schedule... they haven't done more than they have to position it in a way that would enable new $ to come in to support it AS that. Twisting in the wind as it is... must suggest there is still SOMETHING here making not worth pulling the plug and starting over ?
You must have a literary and spiritualist background! thnx anyway! lets us know when it draws your active interest?
I think it would be worth calling the company to see what they are up to, and what they expect...
Otherwise, I think what is occurring in the debt is vastly more of a problem than anything being presented as a positive in the lab or in the trials, and you need to parse Bay interest more than VIAP value or potential. Bay is doing far more to remove value than VIAP is to create it.
Value has to remain attached to a share to BE value, and the risk being posed here is uncertainty over what a share represents. Dilution sucks... and that IS the mode of the day, here.
I've been a holder and a trader in the past. For now, I don't see they are posturing a reason to expect there will be a reward offered for taking the risks. I'm on the sidelines until there is clarity on focus and intent, along with an ability to see what the market drivers and time lines are going to be.
Nope. Not me...
Anyone into VIAP? armani emperium and downsideup any of you? expectations/?
tia
mlkr
OT: Did u guys check out CVM, GETA, GNBT, DSCO break outs and pull backs in some? anyone in them?
Downsideup: My co moderator's name in another board is up-down. similar to yours. is this just coincidence or do you also use up-down as well?
tia
I'm liking NPHC. Near term...
I'll still disagree on the probable utility of their focus, here, but, they don't seem to have done the job, yet, that THEY think they need to do in order to solve the puzzle they thought they had solved. They work they've done here seems to show that the science was wrong... that what they thought they knew about how these inflammation problems worked in heart disease had a basis in science that was only partly correct. Reality seems it is a bit more complex...
That may or may not mean that they are back to the level of having this be a basic science project...
The inlicensing effort suggests either that they have an idea or two about the complexities, and how to address them, based on other prior work... or, it means they are shifting gears back to other ideas that their science team understands ?
The posture Bay is showing us suggests they think either that they are back to needing to take a bit more control over the effort, or that they really want a bit more of the benefit of any future success ?
In any case, the project seems not to be moving smartly along toward Phase III and big partnering deals, now, rather than pausing to think about things again.
It has me wondering whether they (broadly) have properly parsed the elements of changing sources of inflammation in blood vessels, which might matter more than only understanding some portion of the biochemistry in the responses assuming a particular source as a cause. Perhaps the metabolism of corn syrup sweetners as they have become endemic has altered the pathways and modified the functions, somewhat ? It seems to me they have new information, from the studies they've done, which SHOULD position them to have an advantage or two over others, from here, in figuring it out... but, while that does leave you needing to solve new problems, once you figure out what the problems ARE... IOW, back to a science project... it doesn't really do much to illuminate how good a bead they have on the issues... or how quickly they might both figure it out and come up with corrections to address the issue... or how much that will matter in terms of needing to start over again at phase I vs. moving along to phase III ?
The imaging studies showed meaningful changes... the primary problem with them being that the positive results didn't correlate with their assertions of the methods of function they expected... That blows some bit of their science out of the water, but it still doesn't convert what IS a good result into a bad result.
I did some DD the other day im not impressed with this pipeline of drugs one bit , radar RNN now thats a fine company could be the next HGSI in a year
Ouch. Why cut them once, when you can just hack and slash them over, and over, and over ? Do it again once a month ? Why not ?
All I see is a massive threat being postured over and over... making you wonder why THEY see a benefit for themselves in posturing that sort of "market support" for their portfolio companies ?
OK. We get it. This company belongs to Bay City Capital, lock, stock and barrel...
So, now, what good is that ?
Can't say what I see here is going to send me looking for any others with the benefit of Bay City sponsorship.
8-K Filing is out.
http://yahoo.brand.edgar-online.com/default.aspx?companyid=8477
Kind of an odd move, given the total lack of news, and nothing much to expect coming along on the timeline we can see, other than running out of money again ?
VIAP- might be the time to buy
http://stockcharts.com/h-sc/ui?s=viap&p=D&b=5&g=0&id=p23463897154
There are a couple of ways to look at it...
Obviously it is not good for holders to suffer massive share dilution or to have to accept financing from Bay on terms a loan shark would be proud to offer.
It is also not the case that Bay has ever NOT been in control of the situation. They have been from the start and still are the sponsor who are keeping it afloat... and more than the company itself, they are responsible for the effort being made, or not, in enabling the effort to get more and better financing on better terms, whether by convertible debt, by selling shares, or by selling off some of the company or its product development efforts.
So, is it the case that Bay is doing what they are now because they are unhappy with the results in development, thus far... and are in fact unable to sell it to any others, or to arrange others participation ? Or, is it the case that Bay is happy enough with what they see, thus far... and are in position to easily manage it in a way that enables growth in their own interest, which seems it is an interest in having a vastly larger participation ?
For investors, I think you need to see all sides of the impact of having the sort of sponsorship they do...
For now, that creates an ongoing need to balance the obviously growing risks of dilution with preservation of the potential for success over time. I expect Bay isn't holding shares and growing their stake with additional $ added now because they intend to dump the shares they get on the market to drive share prices down... instead of thinking that they have determined it is in their larger interest to own more now.
They have to know that the only way they will get their prior and current additional investment back out is to have the development effort succeed and make it worth more. Looks to me like their plan is still to have it succeed, and to cash out only when there is a larger success of the sort that enables making a deal with a major. They aren't angling for "more shares to sell"... rather than managing the percentage of the total interest that their holding represents ?
You still need to see that the cost of the $ has gone up... and need to parse why...
Given that, you probably need to parse their current moves to determine whether Bay are making the moves that we see they are because they don't really have any better options now to share the risks, or are they making them as they are because they do have options, and the market power, both to enable the company to be successful, and to manage the level of the reward that they will get for enabling that success.
On a more technical basis, you might ask basically the same questions in terms of the recent moves we've seen that have them inlicensing rights to some other products. Are they doing that in a way you should see as indicating problems with the primary focus, or are they doing that in a way that appears to be synergistic with the primary focus ?
What pretty obviously is not on the table now... are deals of the sort that would require them to be able to deliver a result that the market could value...
I think the end result of merging that broad set of elements for consideration... is that Bay apparently sees "enough" progress from phase II to want to ensure it gets through phase III even if that means doing it with their own $. With hind sight, some elements of phase II could have been better designed. They probably would have been "if they knew then". They made some good adjustments on the fly that helped. But, you don't know what you don't know until you know it.
Bay also apparently sees the opportunity to leverage what they have in hand now by bringing in other potentially synergistic values. That is potential value you get as a benefit from knowing now what you didn't before... but it leaves open many more questions than before about the meaning of problems tied to what they thought they knew that was shown to be wrong... a virtual definition of the result as a technical success that shows up as a new source of larger market risk.
Bay remains committed. That matters, perhaps most. However, the attachment of a % of the total value to a common share shows the relative portion of value each share represents slipping down a steep slope... and Bay alone controls the tilt of the field.
I think you can appreciate that Bay's participation provides value, and appreciate that the work being done seems it is being done in a way that has them making real progress toward the goal, but still can't make a rational commitment to buying shares until you see a more rational design in terms of plans that have potential to do more than provide stop gap funding in small steps that erects in a series of new dilution steps, larger hurdles as each new deadline approaches.
Ultimately, Bay's choices seem they will define others. If they provided the same money in larger piles, for less of the company in each new addition to the pot as progress is made, they'd be defining for us that they see a larger and larger value being grown over time. That isn't what they are saying with what they are doing... so, are they telling us the truth with what they are doing... or, are they "loading up" while positioning it to enable that, and posturing it as they are for purpose ?
All of that matters... but, my bottom line focus is still to make money, not just to pick winners, and to do that I need to buy low, not hold on against hope and reason while open ended dilution risks are postured in a way that drives the value of holdings lower and lower. I don't expect you will see an actionable bottoming pattern on a chart... until you can see a limit to the risks that are being postured. I think VIAP has higher than average potential to be a big drug sweepstakes winner... but, the shifts in the odds in the game matter. No clear winners came out of the second round drawing, which means each ticket in the next drawing in the third round has much less chance of being picked as the winner of an still undivided interest in the outcome in the next round?
Dilution sucks... and more dilution sucks more.
Bay capital's financing: details--
VIA Pharmaceuticals Inc. drew down $2 million from a note and warrant agreement with Bay City Capital funds.
The San Francisco biotech company (NASDAQ: VIAP) said the money — the third $2 million draw down since mid-March — for general corporate purposes, according to a filing Monday with the Securities and Exchange Commission. It took the other cash on March 12 and May 19.
Amounts borrowed under the notes accrue interest at the rate of 15 percent per year, increasing to 18 percent following a default. The notes are due Sept. 14 or — if they happen sooner than that — the closing of more than $20 million in debt or equity financing or in the case the company is sold, merged or substantially reorganized.
With the latest borrowing, 8.3 million of some 83.3 million warrant shares that VIA granted in March to Bay City Capital immediately vested. Another 8.3 million shares could vest by mid-August if certain conditions are met, according to the SEC filing.
VIA may take an additional $4 million as part of the agreement.
VIA focuses on developing drugs to treat cardiovascular and metabolic disease. Its lead compound, VIA-2291, has completed a Phase IIa trial. A Phase III study is planned to study whether the drug can prevent heart attack, stroke and other cardiovascular events.
delisting letter and new money withdrawn: 2 million dollars.. sept 09 pay bach deadline.. Trial 2nd stage..
Friday, July 17, 2009
VIA pharma gets delist warning
Silicon Valley / San Jose Business Journal
Related News
* VIA takes another $2M from Bay City Capital
* VIA Pharmaceuticals in licensing deal with Roche
* VIA chief medical officer lands consulting gig with … VIA
VIA Pharmaceuticals Inc. said Friday it received a delist warning from Nasdaq because it doesn't meet the requirement for $2.5 million in minimum stockholders' equity.
San Francisco-based VIA (NASDAQ:VIAP), a biotechnology company focused on cardiovascular and metabolic disease, said it intends to file an appeal before Nasdaq's listing qualifications panel.
The company's shares have traded between 8 cents and $2.23 in the past 52
reality check;
"I am starting to become more familiar with VIAP and I clearly see the risk/reward as cited by others on this msg board.
My largest concerns are that VIA Pharm has no immediate source of revenue, they have borrowed millions at 15% interest and have planned to issue more than 83 million new shares at par value of $0.12
that creates immense downward pressure. on top of that, the latest filing shows that "...all unpaid principal and accured interest shall become fully due and payable on the earliest to occur of (i) September 14,2009"
Everything hinges on the success of VIA-2291 which hasn't even entered into Phase III (although it will soon and is, to date successful) This won't be marketable for a min. of one more year (in a perfect world) so with no revenue source, and next to no cash (which is being borrowed at credit card rates) I don't see this company taking off anytime soon.
If it dips to $0.12 to $0.22 range, I might speculate and hope for a buy out at a larger share price but....this is not CTIC or DNDN. Even at CTIC darkest days ($0.05/share) the market cap was over $25 million so they didn't have to be too seriously concerned with a delist threat....but VIAP?"
by Rodgerdalpy YMB
Overall take:
http://www.stoxline.com/quote.php?symbol=viap
Looks like I won...
I don't think some number of IHub posts are actually a necessary check in the box you need to have before a stock can trade... ;<)
The story here is a lot more straightforward now than it has been...
Charts show a conflict, with the golden cross on the daily charts showing the 200 MA as new support along with all the other daily MAs moving up providing support...
The trade we see recently correlates with the shares trading down along the 50 MA on the weekly charts, with it getting close to the lower bollie, around $0.425 now, and moving up.
Conflict between the two looks like it will be resolved... but, the broader market might have more to do with how it trades than the charts for the next while.
I'll watch to see that it holds around $0.425ish, and then expect it might move higher.
I don't see that there is much other than the patterns in the market noise (charts) to guide trading for now. The fundamentals are what they are... they have the $ they need to move forward with the work they are doing, phase III... but, don't have the $ to get through phase III. The success of the work is obviously critical, and that looks good...
The downside is the number of shares vesting each time they draw down $ on borrowings from their sponsor... the interest rates they are or might be paying... and the lack of a large enough pile of $ to see them through. Still, I don't get the feel that Bay City Capital is unhappy with the deal they got.
Convertibles suck... but if they hit it out of the park by gaining some synergies from the drugs they are developing and those they bought in recently, no one will complain...
I'll guess it might trade down to $0.425 before it moves off the chart patterns it is following now... but don't have much of a guess what it will take, or when it will happen, before it does more than trade within the patterns in noise.
upsidedown/downsideup
"Golden cross" or "golden shower"?
chart please?
tia
Hmmm. IF there are like 700K or more short, and 37K in volume does this... there are some seriously screwed shorts ?
Shorts in the trade... knowing the sponsorship... ???
Golden cross today...
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
695
|
Created
|
04/11/06
|
Type
|
Free
|
Moderators |
Who is VIA Pharmaceuticals?
VIA Pharmaceuticals, Inc., a biotechnology company, focuses on developing compounds for the treatment cardiovascular diseases. The company is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Its pipeline includes small molecule anti-inflammatory drugs that intervene directly in vascular inflammation pathways. The company's principal product, VIA-2291, is in two concurrent Phase II clinical studies in patients with acute coronary syndrome and patients with carotid artery stenosis. VIA Pharmaceuticals was founded in 2004 and is headquartered in San Francisco, California.
What's in their pipeline?
Our pipeline includes preclinical and clinical-stage small-molecule drugs that intervene directly with selected molecular targets in pathways of interest in cardiovascular and metabolic disease.
What's happening at VIA Pharmaceuticals?
VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ Oct 13, 2009 | 10.2 KB | ||
SAN FRANCISCO, Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market ("... | |||
VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ Sep 28, 2009 | 10.4 KB | ||
SAN FRANCISCO, Sept 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on September 23, 2009, it received a deficiency letter from The NASDAQ Stock Market n... | |||
VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ Sep 18, 2009 | 10.1 KB | ||
SAN FRANCISCO, Sept 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on September 15, 2009, it received a deficiency letter from the NASDAQ Stock Market s... | |||
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ Jul 17, 2009 | 9.8 KB | ||
SAN FRANCISCO, July 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it received a Staff Determination letter, dated July 15, 2009, from the NASDAQ Stock ... | |||
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease Jun 11, 2009 | 10.6 KB | ||
SAN FRANCISCO, June 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that an end of Phase 2a meeting for the Company's lead drug, VIA-2291 (atreleuton), was re... | |||
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation Jun 4, 2009 | 10.5 KB | ||
SAN FRANCISCO, June 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that preclinical data related to diacylglycerol acyl transferase - 1 (DGAT1) inhibitors wil... | |||
VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients May 14, 2009 | 11.8 KB | ||
SAN FRANCISCO, May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed enrollment in a Phase 2 clinical trial of its lead drug, VIA-2291 in ... | |||
VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque May 1, 2009 | 11.5 KB | ||
WASHINGTON and SAN FRANCISCO, May 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP) today announced the results of a sub-study of patients in its acute coronary syndrome (ACS) Phase 2 trial who received serial 64 slice multidetector computed tomography (MDCT) scans before and after six months of trea... | |||
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ Apr 3, 2009 | 9.8 KB | ||
SAN FRANCISCO, April 3, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has received a letter, dated March 31, 2009, from the staff of the NASDAQ Stock Ma... | |||
VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009 Mar 31, 2009 | 10.3 KB | ||
SAN FRANCISCO, March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that an abstract on the Company's Phase 2 clinical trial of VIA-2291 has been accepted fo... | |||
VIA Pharmaceuticals Complies With NASDAQ Rules Mar 27, 2009 | 9.9 KB | ||
SAN FRANCISCO, March 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit rep... | |||
VIA Pharmaceuticals Secures Financing Up to $10.0 Million Mar 12, 2009 | 10.3 KB | ||
SAN FRANCISCO, March 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced it has entered into a $10.0 million secured note purchase agreement (together with certai... | |||
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 Feb 25, 2009 | 9.6 KB | ||
SAN FRANCISCO, Feb 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for... | |||
VIA Pharmaceuticals Licenses Drug Candidates from Roche to Expand Cardiovascular Pipeline to Include Metabolic Disease Dec 23, 2008 | 10.7 KB | ||
SAN FRANCISCO, Dec 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced exclusive, worldwide licensing agreements with Roche (SWX: ROG) for two sets of compounds. The first ... | |||
VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease Nov 9, 2008 | 17.2 KB | ||
NEW ORLEANS and SAN FRANCISCO, Nov 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today the results of two Phase 2 studies of its lead drug, VIA-2291. In each Phase 2 study, VIA... | |||
VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA Nov 6, 2008 | 7.1 KB | ||
SAN FRANCISCO, Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will hold a conference call and webcast to discuss results of the VIA-2291 Phase 2 acute coronary... | |||
VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations Nov 4, 2008 | 6.7 KB | ||
SAN FRANCISCO, Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that VIA management will present at three upcoming investor conferences. The presentation detai... | |||
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial Sep 24, 2008 | 10.3 KB | ||
SAN FRANCISCO, Sept 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed the last patient visit in its Phase 2 acute coronary syndrome (ACS) study, includi... | |||
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008 Sep 15, 2008 | 9.9 KB | ||
SAN FRANCISCO, Sept 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that two abstracts on the company's Phase 2 trials of VIA-2291 in patients with acute coronary syndrome ... | |||
VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 Sep 9, 2008 | 10.8 KB |
What about the merger with Corautus Genetics?
Date of Event: 02/08/2007
ATLANTA and SAN FRANCISCO, Feb. 8 /PRNewswire-FirstCall/--Corautus Genetics Inc. (Nasdaq: VEGF - News) and VIA Pharmaceuticals, Inc., a privately-held drug development company headquartered in San Francisco, California, today announced they have signed a definitive merger agreement. The merger is expected to create a drug development company focused on compounds that target inflammation in the blood vessel wall as an innovative approach to the treatment of cardiovascular disease.
The combined company's lead product candidate will be VIA-2291, a small- molecule drug that targets inflammation in the blood vessel wall, believed to be a key disease process in atherosclerosis. VIA filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the first quarter of 2006 and is currently conducting two Phase II clinical trials of VIA-2291 treating vascular inflammation in patients undergoing Carotid Endarterectomy and patients at risk for recurrent cardiovascular events following Acute Coronary Syndrome.
Richard Otto, Chief Executive Officer of Corautus, said "The Corautus team has spent the past several months reviewing strategic opportunities. The novel therapeutic development program underway at VIA addresses a large cardiovascular patient population. In addition, the substantial support of Bay City Capital, VIA's principal stockholder, and the experience of the VIA management team were key strengths as we evaluated this merger. We are pleased to be making this announcement and to combine our assets with VIA's exciting clinical development plans to develop novel therapeutic treatments for cardiovascular diseases."
Lawrence Cohen, Ph.D., Chief Executive Officer of VIA, said "We are very pleased to combine with Corautus and view this as the beginning of an exciting new chapter in the growth of VIA as an innovative and dynamic biopharmaceutical development company. The proposed transaction will strengthen our financial position and bring significant new shareholders to our strong existing investor, Bay City Capital. VIA is working closely with Corautus and its existing stockholders to maximize the value of our combined companies."
Details of the Proposed Transaction
The merger agreement has been approved by the Boards of Directors of Corautus and VIA. Under the terms of the Agreement, Corautus will issue, and VIA stockholders will receive, shares of Corautus common stock in exchange for their shares of VIA stock. It is expected that VIA stockholders will own approximately 76.4% and existing Corautus stockholders will own approximately 23.6% of the combined company on a pro forma, fully-diluted basis based on the delivery of $12 million of net cash at closing (the actual percentages to be determined based on Corautus's net cash at closing). The merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the U.S. Internal Revenue Code of 1986, as amended. The transaction is subject to Corautus maintaining certain minimum cash levels, as well as certain other customary conditions, including obtaining stockholder approval. Corautus stockholders holding approximately 34% of the outstanding voting stock of Corautus and Bay City Capital holding approximately 89% of the outstanding voting stock of VIA have entered into voting agreements whereby they have agreed to vote their shares in favor of the merger. Prior to closing, VIA intends to apply to have the combined company's common stock approved for initial listing on the NASDAQ Capital Market under the symbol "VIAP". The transaction is expected to close in the second quarter of 2007.
Following the closing of the transaction, Lawrence Cohen, Ph.D., Chief Executive Officer and President of VIA will become Chief Executive Officer and President of the combined company. James G. Stewart, Senior Vice President, Chief Financial Officer of VIA will become the combined company's Chief Financial Officer. Oye Olukotun, MD, MPH, FACC, Chief Medical Officer of VIA will become Chief Medical Officer of the combined company. The combined company's board of directors is expected to consist of seven directors, consisting of three current directors of VIA, one current director of Corautus and three directors to be named by VIA prior to closing the merger.
Morgan Keegan & Co., Inc. served as financial advisor to Corautus. Lazard Freres & Co. LLC served as financial advisor to VIA.
Additional Information about the Merger and Where to Find It
In connection with the proposed transaction, Corautus expects to file a proxy statement and other materials with the Securities and Exchange Commission (SEC). Corautus stockholders are urged to read the proxy statement (including any amendments or supplements to the proxy statement) regarding the proposed transaction when it becomes available before making any voting decision with respect to the merger. The proxy statement will contain important information about Corautus, VIA and the proposed transaction. Corautus' stockholders will be able to obtain a copy of the proxy statement and other relevant documents, when they become available and without charge, at the SEC's Internet site (http://www.sec.gov). Copies of the proxy statement, the other relevant documents and the filings with the SEC that will be incorporated by reference in the proxy statement can also be obtained, without charge, by directing a request to Corautus Genetics Inc., 70 Mansell Court, Suite 100, Roswell, Georgia 30076, Attention: Jack Callicutt, Telephone: (404) 526-6210.
Participants in the Solicitation
Corautus and its directors and executive officers and VIA and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Corautus in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the merger transaction will be included in the proxy statement referred to above. Additional information regarding the directors and executive officers of Corautus is also included in Corautus' proxy statement for its 2006 Annual Meeting of Stockholders, which was filed with the SEC on April 4, 2006.
About Corautus Genetics Inc.
Corautus is a development stage company dedicated to the development of innovative products in the life sciences industry. Corautus, formerly known as GenStar Therapeutics Corporation and Urogen Corp., was formed as a Delaware corporation on June 30, 1995. Prior to November 1, 2006, Corautus was primarily focused on the clinical development of gene therapy products using a vascular growth factor gene, Vascular Endothelial Growth Factor 2 (VEGF-2), for the treatment of severe cardiovascular disease. Corautus was the sponsor of a Phase IIb clinical trial to study the efficacy of VEGF-2 for the treatment of severe cardiovascular disease, known as the GENASIS trial.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a drug development company focused on compounds that target inflammation in the blood vessel wall, as an innovative approach to treatment of cardiovascular disease. Inflammation in the blood vessel wall recently is believed to have a fundamental role in all stages of atherosclerosis, and in precipitating heart attacks and other acute cardiovascular events. VIA scientists specialize in the field of vascular (blood vessel) inflammation and cardiovascular disease, and the company's management team has extensive pharmaceutical industry experience. VIA Pharmaceuticals, Inc. is a privately-held company headquartered in San Francisco, CA.
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements that address performance, events or developments that we expect or anticipate will occur in the future, such as the likelihood of identifying and securing life sciences opportunities upon which to focus our resources and the adequacy of our cash position to transition to new opportunities if found. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risk factors in Corautus' 2005 Annual Report on Form 10-K which was filed on March 20, 2006, as amended by Corautus' Form 10-Q for the periods ending March 31, 2006 which was filed on May 15, 2006, and September 30, 2006 which was filed on November 14, 2006, all of which are incorporated by reference into this release. All forward-looking statements included in this release are based on information available to Corautus on the date hereof, and Corautus assumes no obligation to update any such forward-looking statements.
Contact Information:
Corautus Genetics Inc.
Jack W. Callicutt
Senior Vice President and Chief Financial Officer
404.526.6210
VIA Pharmaceuticals, Inc.
James G. Stewart
Senior Vice President and Chief Financial Officer
415.283.2204
Source: Corautus Genetics Inc.
___________________________________________________________________
SAN FRANCISCO, CA, June 5, 2007 - VIA Pharmaceuticals, Inc. (NASDAQ: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today the completion of its merger transaction with Corautus Genetics Inc. and its receipt of an extension from the NASDAQ Listings Qualifications Panel until June 29, 2007 for the company to comply with applicable initial listing standards.
Following the closing of the merger transaction, Corautus was renamed "VIA Pharmaceuticals, Inc." As a result of the previously announced 1:15 reverse stock split and the issuance of shares of Corautus common stock to VIA stockholders in the merger transaction, the company now has 9,430,607 shares of common stock issued and outstanding. Pre-merger Corautus stockholders own approximately 22% and former VIA equity holders own approximately 78% of the capital stock of the company, determined on a fully-diluted basis.
VIA's lead product candidate is VIA-2291, a small-molecule drug that targets inflammation in the blood vessel wall, believed to be a key disease process in atherosclerosis. VIA is currently conducting two Phase II clinical trials of VIA-2291 treating vascular inflammation in patients at risk for recurrent cardiovascular events following acute coronary syndrome and patients undergoing carotid endarterectomy.
"The launching of VIA as a public company through our merger with a strong group of existing Corautus stockholders, is an important milestone in our corporate development and enables us to continue the development of our clinical stage pipeline focused on the treatment of cardiovascular disease," said Lawrence Cohen, Ph.D., Chief Executive Officer and President of VIA. "With our lead product, VIA-2291, already in multiple Phase II clinical trials, we have a solid platform to continue development of small molecule drugs that target various stages of vascular inflammation."
The company's common stock will begin trading on the NASDAQ Capital Market under the new ticker symbol "VIAP" on June 6, 2007. On June 5, 2007, the company received notice from the Nasdaq Listings Qualification Panel that the panel had granted an extension through June 29, 2007 for the company to meet initial listing standards, provided that it demonstrate compliance with continued listings standards, including a minimum closing bid price of $1.00 or more through June 19, 2007. In addition, the exception is conditioned on the company meeting the $15 million minimum public float requirement on or before June 29, 2007 and maintaining such float for a period of at least ten consecutive trading days prior to July 16, 2007.
As previously disclosed, effective upon the closing of the merger transaction, new officers and directors of the company were appointed. Lawrence Cohen, Ph.D., will serve as Chief Executive Officer and President. James G. Stewart will serve as Chief Financial Officer. Oye Olukotun, MD, MPH, FACC, will serve as Chief Medical Officer. The board named Douglass B. Given, M.D., Ph.D. as Chairman and is comprised of the following additional six directors: Richard L. Anderson, Mark N.K. Bagnall, Lawrence K. Cohen, Ph.D., Fred B. Craves, Ph.D., David T. Howard and John R. Larson.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. VIA's lead drug candidate, VIA-2291, is in two concurrent Phase II clinical studies in patients with cardiovascular disease. VIA is headquartered in San Francisco, CA. For more information, visit: www.viapharmaceuticals.com.
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements that address performance, events or developments that we expect or anticipate will occur in the future, such as the company's ability to satisfy the initial listing requirements of the NASDAQ Capital Market and remain listed, the company's potential for future growth and the development of the company's operations and product pipeline. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risk factors in Corautus Genetics Inc.'s Definitive Proxy Statement on Schedule 14A, which was filed on May 10, 2007 (as subsequently supplemented), Corautus Genetics Inc.'s 2006 Annual Report on Form 10-K, which was filed on March 30, 2007, as amended by Corautus Genetics Inc.'s Form 10-K/A for 2006, which was filed on April 30, 2007 and Corautus Genetics Inc.'s Form 10-Q for the period ended March 31, 2007, which was filed on May 15, 2007, all of which are incorporated by reference into this release. All forward-looking statements included in this release are based on information available to VIA on the date hereof, and VIA does not assume any obligation to update any such forward-looking statements.
Contact Information:
VIA Pharmaceuticals, Inc.
James G. Stewart
Senior Vice President and Chief Financial Officer
415.283.2204
The Trout Group
Ian Clements / Lauren Glaser - San Francisco - 415.392.3385
Brian Korb - New York City - 646.378.2923
Stock Information?
Via Pharmaceuticals, Inc. is traded on the Nasdaq Capital Market under the symbol VIAP.
~20.6 Million O/S
1:15 Reverse Split put into effect on June 6, 2007
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |